title: [Therapy of neovascular glaucoma. The outcome of IOP using concomitant therapy consisting of retinal kryocoagulation, diode laser coagulation, and intravitreal injection of bevacizumab].
abstract: BACKGROUND
  Intravitreal Bevacizumab has been used as adjunct treatment to diode laser cyclophotocoagulation and/or retinal photo-/cryocoagulation in eyes with neovascular glaucoma and is discussed to reduce intraocular pressure and rubeosis irides in addition.
  
  
  METHODS
  This study investigated the drop of the intraocular pressure of 23 patients who were treated by a concomitant therapy consisting of retinal kryocoagulation, diode laser coagulation and intravitreal injection of Avastin(®) administered in one session.
  
  
  RESULTS
  At the time of discharge patients exhibited a 55.1 % (19.7 mmHg) decrease in intraocular pressure and also a 48.7 % (17.4 mmHg) decrease in regard to follow-up results. Topical agents were not significantly decreased with 2.1 agents at the beginning of treatment and 1.9 at the time of discharge. Furthermore, the systemic administration of acetazolamide was reduced from 12 patients at the beginning to 2 patients at the time of discharge. In 21 cases the intraocular pressure returned to normal levels, whereas the other two patients were pain-free after treatment.
  
  
  CONCLUSIONS
  With the administration of triple therapy, the intraocular pressure showed a significant reduction. There were no severe complications and the symptoms also were improved significantly.
authors.affiliation: Augenklinik Campus Benjamin Franklin, Charité Berlin, Germany. ira.seibel@charite.de
authors.forename: I
authors.initials: I
authors.lastname: Seibel
authors.forename: H
authors.initials: H
authors.lastname: Breuss
authors.forename: J
authors.initials: J
authors.lastname: Kuchenbecker
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005260:Female; D015355:Glaucoma, Neovascular / Q000628:therapy*; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000187:drug effects; D053685:Laser Therapy; D054023:Lasers, Semiconductor / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab